Key Takeaways for Neratinib Plus T-DM1 Combination in Breast Cancer
Jame Abraham, MD, discusses the key takeaways from the phase Ib study of trastuzumab emtansine in combination with neratinib in patients with HER2-positive breast cancer.
Jame Abraham, MD, professor of medicine at the Cleveland Clinic and co-director of the Cleveland Clinic Comprehensive Breast Cancer Program, discusses the key takeaways from the phase Ib study of trastuzumab emtansine (T-DM1) in combination with neratinib (Nerlynx) in patients with HER2-positive breast cancer.
First, Abraham says that the trial shows T-DM1 is an active regimen in combination with neratinib for patients who progress or are refractory to trastuzumab (Herceptin) and pertuzumab (Perjeta). With a dose of neratinib at 160 mg, the combination had deep responses in this patient population.
Durability and Intracranial Efficacy Observed With T-DXd in HER2+ MBC
January 13th 2025During a Case-Based Roundtable® event, Ian Krop, MD, and participants discussed how the outcomes of the DESTINY-Breast03 and other trials impact treatment of metastatic HER2-positive breast cancer in the second article of a 2-part series.
Read More
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
Enasidenib Shows Promise as Post-Transplant Maintenance in IDH2-Mutated AML
January 7th 2025Amandeep Salhotra, MD, discussed the background and findings from a pilot trial evaluating enasidenib as post-hematopoietic stem cell transplant maintenance therapy for IDH2-mutated acute myeloid leukemia treatment.
Read More
Could Triapine With Lutetium 177 Dotatate Improve Outcomes for Neuroendocrine Tumors?
December 30th 2024Aman Chauhan, MD, highlights an ongoing phase 2 trial exploring the combination of triapine, a radiation sensitizer, with lutetium 177 dotatate for treating well-differentiated somatostatin receptor–-positive neuroendocrine tumors.
Read More
